INOSR Scientific Research 12(3):5-12, 2025. **ISSN: 2705-1706**
©INOSR PUBLICATIONS **INOSRSR12300000**
International Network Organization for Scientific Research
https://doi.org/10.59298/INOSRSR/2025/123512

Targeted Nanodelivery Systems of Herbal Antioxidants for Precision Management of Obesity and Type 2 Diabetes

Nyiramana Mukamurera P.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Obesity and type 2 diabetes mellitus (T2DM) represent interrelated global health challenges with increasing morbidity and mortality. Oxidative stress is a shared pathological feature contributing to insulin resistance, adipose tissue dysfunction, and systemic inflammation in both conditions. Herbal antioxidants have emerged as promising therapeutic agents due to their ability to scavenge free radicals, modulate signaling pathways, and restore redox balance. However, limitations such as poor bioavailability, instability, and rapid metabolism have hindered their clinical translation. Recent advances in nanotechnology offer a compelling solution through targeted nanodelivery systems, enhancing the pharmacokinetics and therapeutic efficacy of phytochemicals. This review explores the latest developments in nanoparticle-based delivery of herbal antioxidants for precision management of obesity and T2DM. We highlight major classes of nanocarriers, including liposomes, polymeric nanoparticles, solid lipid nanoparticles, dendrimers, and nanoemulsions, and their applications in delivering bioactive compounds like curcumin, resveratrol, quercetin, catechins, and berberine. The review further discusses mechanisms of action, targeting strategies, challenges, and future directions in personalized nanomedicine for metabolic disorders.

Keywords: Obesity, Type 2 Diabetes, Herbal Antioxidants, Nanodelivery Systems, Targeted Therapy, Oxidative Stress, Curcumin, Resveratrol, Phytochemicals, Precision Medicine

INTRODUCTION

Obesity and type 2 diabetes mellitus (T2DM) are interrelated, multifactorial metabolic disorders that pose significant global health challenges[1–3]. These conditions are characterized by excessive adipose tissue accumulation, insulin resistance, hyperglycemia, and a state of chronic low-grade inflammation[2, 4, 5]. Contributing factors include the widespread adoption of sedentary lifestyles, calorie-dense and nutrient-poor diets, and increasing urbanization, compounded by genetic susceptibility. A key pathophysiological mechanism underlying both obesity and T2DM is oxidative stress, which arises from an imbalance between reactive oxygen species (ROS) production and the body's endogenous antioxidant defense systems[6–8]. This oxidative stress exacerbates insulin resistance, impairs pancreatic β-cell function, promotes adipocyte dysfunction, and enhances the inflammatory cascade, thereby perpetuating the progression of these metabolic disorders[9, 10].

In the quest for effective and safer therapeutic strategies, plant-derived antioxidants have gained significant attention. These naturally occurring compounds, including flavonoids, polyphenols, and terpenoids, are abundant in medicinal herbs and have demonstrated potent antioxidant, anti-inflammatory, and insulin-sensitizing properties in preclinical studies[11–13]. Despite their promising pharmacological profiles, the clinical utility of herbal antioxidants remains limited due to challenges such as poor aqueous solubility, low gastrointestinal absorption, metabolic instability, and limited ability to reach target tissues in therapeutically effective concentrations. These pharmacokinetic and pharmacodynamic limitations hinder their bioefficacy and therapeutic outcomes, necessitating innovative solutions that can enhance their delivery, bioavailability, and target specificity. Nanotechnology has emerged as a transformative approach to address these challenges by engineering nanoscale delivery systems that encapsulate herbal antioxidants, thereby protecting them from premature degradation and enhancing their solubility and absorption[14–17]. Nanocarriers such as liposomes, polymeric nanoparticles, solid lipid nanoparticles, and nanoemulsions are being explored for their ability to facilitate controlled release, prolong circulation time, and enable site-specific delivery of bioactives to insulin-sensitive tissues such as the liver, adipose tissue, and skeletal muscle[18–20]. This review critically examines the current advancements in targeted nanodelivery systems for herbal antioxidants, emphasizing their potential to revolutionize the prevention and treatment of obesity and T2DM. By integrating traditional herbal

knowledge with modern nanotechnology, these novel delivery platforms offer a promising avenue for developing more effective, safer, and patient-friendly therapeutic interventions for these prevalent metabolic disorders.

Oxidative Stress in Obesity and Type 2 Diabetes

Oxidative stress plays a pivotal role in the development and progression of metabolic dysfunctions by disrupting cellular redox balance and impairing essential metabolic pathways. In obesity, the accumulation of excessive adipose tissue, particularly visceral fat, leads to an increase in reactive oxygen species (ROS) production[21–23]. This is primarily driven by hypertrophic adipocytes and infiltrating immune cells such as macrophages, which contribute to a pro-inflammatory environment. The elevated ROS levels induce mitochondrial dysfunction and endoplasmic reticulum (ER) stress, further aggravating adipocyte dysfunction. These alterations impair insulin signaling pathways and promote the dysregulated secretion of adipokines—such as leptin, adiponectin, and resistin—thereby fueling systemic inflammation and insulin resistance[24–26]. Similarly, in type 2 diabetes mellitus (T2DM), chronic hyperglycemia exacerbates oxidative stress through multiple mechanisms, including glucose auto-oxidation, non-enzymatic glycation of proteins, and the activation of the polyol and hexosamine biosynthetic pathways[27]. These processes result in excessive ROS generation, leading to cellular damage, particularly in insulin-producing pancreatic β-cells, which are highly vulnerable to oxidative injury due to their low antioxidant capacity[28]. The resultant β-cell dysfunction and apoptosis contribute to the progressive decline in insulin secretion seen in T2DM. Therefore, oxidative stress not only initiates but also perpetuates metabolic derangements[28]. Targeting oxidative stress through antioxidant therapies or interventions that enhance endogenous antioxidant 6avourab represents a promising therapeutic strategy to mitigate insulin resistance, curb chronic inflammation, and prevent or delay the onset of metabolic disorders such as obesity and T2DM.

Herbal Antioxidants and Their Therapeutic Potential

Many phytochemicals exhibit strong antioxidant and antidiabetic properties. Key examples include:

Compound	Source	Mechanisms of Action	References
Curcumin	*Curcuma longa*	Inhibits NF-Kb, improves insulin sensitivity, reduces adipogenesis	[29, 30]
Resveratrol	Grapes, red wine	Activates SIRT1/AMPK, enhances mitochondrial function, reduces inflammation	[31–33]
Quercetin	Apples, onions	Scavenges ROS, modulates PI3K/Akt 6avourable, improves glucose uptake	[34, 35]
Catechins	Green tea	Inhibits lipid accumulation, improves insulin secretion	[36]
Berberine	*Berberis vulgaris*	Activates AMPK, modulates gut microbiota, improves glucose metabolism	[37–39]

Despite their promise, the therapeutic efficacy of these compounds is constrained by suboptimal pharmacokinetics, which nanodelivery platforms aim to improve.

Nanotechnology-Based Delivery Systems: An Overview

Liposome: Liposomes are spherical vesicles composed of one or more phospholipid bilayers that enclose an aqueous core[40, 41]. Their structure mimics biological membranes, making them biocompatible and versatile carriers for drug delivery. Liposomes can encapsulate both hydrophilic compounds within their aqueous core and hydrophobic molecules within the lipid bilayer, thus offering dual-loading capacity [18, 42]. This unique structural advantage makes them especially useful in delivering a wide range of herbal antioxidants. For instance, curcumin, a potent antioxidant with poor solubility and stability, has shown significantly improved pharmacokinetics when encapsulated in liposomes[42]. Curcumin-loaded liposomes have demonstrated enhanced hepatic targeting, making them particularly beneficial in treating metabolic disorders like obesity-related liver inflammation[43]. These formulations improve not only bioavailability but also therapeutic efficacy by concentrating the active compound at the desired site of action. Additionally, liposomes can be surface-modified to improve targeting specificity and circulation time. They have shown promise in reducing oxidative stress and modulating inflammatory cytokines in preclinical models[43]. The controlled and sustained release profile offered by liposomes further reduces dosing frequency and minimizes systemic toxicity. Overall, liposomes represent a well-established nanodelivery platform for herbal antioxidants with significant clinical translation potential in obesity and related metabolic disorders.

Polymeric Nanoparticles: Polymeric nanoparticles are solid colloidal systems composed of natural or synthetic biodegradable polymers, commonly used for the controlled delivery of bioactive compounds[43, 44]. Frequently employed polymers include poly(lactic-co-glycolic acid) (PLGA), chitosan, and polyethylene glycol (PEG). These nanoparticles offer excellent encapsulation efficiency and the ability to protect labile herbal antioxidants from premature degradation in the gastrointestinal tract[45]. One of the standout features of polymeric nanoparticles is their potential for surface functionalization, allowing for the attachment of ligands, antibodies, or targeting moieties to improve tissue specificity. This enhances their therapeutic potential, especially in chronic diseases like diabetes and obesity. A notable example is the encapsulation of resveratrol—a polyphenolic antioxidant—in PLGA nanoparticles. This formulation significantly improved glucose tolerance, reduced body weight, and decreased adipose tissue accumulation in diabetic rat models[45]. Polymeric nanoparticles also offer

sustained and controlled drug release, reducing the need for frequent administration and minimizing systemic side effects. Their nanoscale size facilitates passive targeting through the enhanced permeability and retention (EPR) effect, and their adaptability to various routes of administration—oral, intravenous, or transdermal—makes them a flexible tool in herbal medicine[44]. Thus, polymeric nanoparticles are a promising strategy for enhancing the therapeutic efficacy of herbal antioxidants in metabolic disorders.

Solid Lipid Nanoparticles (SLNs): Solid lipid nanoparticles (SLNs) are submicron-sized carriers composed of solid lipids stabilized by surfactants. They combine the advantages of both lipid-based and polymeric systems, offering excellent stability, biocompatibility, and the ability to control drug release[17, 46]. SLNs are particularly suitable for encapsulating lipophilic herbal antioxidants, shielding them from degradation and enhancing their bioavailability. These nanoparticles exhibit superior loading capacity and enable prolonged circulation times in vivo. Importantly, the solid lipid core of SLNs maintains a solid state at both room and body temperatures, which aids in the sustained release of the encapsulated agents. One compelling example is berberine-loaded SLNs, which have been shown to enhance insulin sensitivity and exert beneficial effects on the gut microbiota—a critical factor in obesity and type 2 diabetes[46, 47]. These nanoparticles also mitigate the challenges associated with the poor solubility and rapid metabolism of many natural compounds. Their small size facilitates uptake by intestinal cells, improving oral absorption. Furthermore, SLNs can be engineered to respond to environmental triggers or to deliver drugs selectively to specific tissues. With their 7avourable safety profile and scalable production methods, SLNs hold great potential in developing advanced herbal antioxidant therapies for chronic metabolic diseases.

Dendrimers: Dendrimers are highly branched, three-dimensional macromolecules with a central core, interior layers (generations), and multiple functional terminal groups. Their precise architecture allows for a high degree of surface functionality and molecular uniformity, making them ideal candidates for multifunctional drug delivery systems[48]. Dendrimers can encapsulate herbal antioxidants within their internal cavities or attach them to their surface, enabling high drug loading and controlled release profiles. Their multivalent nature supports simultaneous delivery of multiple therapeutic agents, enhancing combination therapy approaches[48]. Additionally, dendrimers can be functionalized with ligands, antibodies, or peptides to facilitate active targeting to specific tissues or cells, such as inflamed adipose tissue or pancreatic β-cells in diabetes management. Due to their nanoscale size and modifiable surfaces, dendrimers improve solubility, stability, and circulation time of herbal compounds[49]. They also offer reduced immunogenicity and toxicity compared to some conventional delivery systems. Although still under preclinical evaluation for many applications, dendrimer-based formulations have shown promising results in enhancing antioxidant activity, reducing oxidative stress, and modulating inflammatory pathways in metabolic and neurodegenerative disease models[49]. Their structural precision and versatility make them an exciting frontier in the nanodelivery of complex herbal therapeutics.

Nanoemulsions: Nanoemulsions are kinetically stable, colloidal dispersions consisting of oil and water phases stabilized by surfactants, with droplet sizes typically ranging from 20 to 200 nm.[50, 51] They possess a high surface area and 7avourable7ion capacity, making them highly effective in improving the bioavailability of poorly water-soluble herbal antioxidants. Nanoemulsions are particularly advantageous for oral and topical delivery due to their ease of formulation and enhanced absorption properties. Their small droplet size facilitates gastrointestinal uptake and rapid onset of action, which is critical in managing metabolic complications. For example, quercetin nanoemulsions[51] have demonstrated significantly improved oral bioavailability and have been shown to reduce fasting blood glucose levels in diabetic models. The incorporation of antioxidants into nanoemulsions helps protect them from enzymatic degradation and facilitates targeted delivery to specific tissues. These systems also allow for easy functionalization and incorporation of additional therapeutic agents or adjuvants. Furthermore, nanoemulsions exhibit favorable rheological properties, making them suitable for diverse administration routes including transdermal patches, sprays, and injectables[50]. Their scalability and cost-effective production make nanoemulsions a practical solution for commercial applications in herbal medicine. As a result, nanoemulsions are emerging as a powerful tool in enhancing the therapeutic outcomes of natural antioxidants in metabolic diseases.

Targeting Strategies in Nanodelivery Systems

Effective targeting strategies are central to maximizing the therapeutic efficacy of nanodelivery systems while minimizing off-target effects. In metabolic disorders such as obesity and diabetes, targeted delivery of antioxidants can enhance therapeutic outcomes by concentrating active compounds at disease-relevant sites such as adipose tissue, liver, and pancreas. Three major targeting strategies are employed: passive, active, and stimuli-responsive targeting.

Passive Targeting: Passive targeting exploits the enhanced permeability and retention (EPR) effect, a phenomenon where nanoparticles preferentially accumulate in inflamed or diseased tissues due to leaky vasculature and poor lymphatic drainage[52]. This is particularly relevant in obesity and associated complications, where tissues like visceral fat and the liver exhibit increased vascular permeability. Passive targeting allows nanoparticles loaded with antioxidants to concentrate at these sites, enhancing local therapeutic action without requiring surface modifications[53]. However, the effectiveness of this approach depends on disease progression and vascular characteristics.

Active Targeting: Active targeting involves modifying the nanoparticle surface with ligands that can bind to specific receptors overexpressed in target tissues. For instance, integrins and leptin receptors are often upregulated in adipose tissue, while asialoglycoprotein receptors are abundant in hepatocytes [54]. Pancreatic β-cells express GLP-1 receptors, making them viable targets in diabetes therapy. By attaching appropriate ligands such as peptides, antibodies, or folate, nanoparticles can achieve site-specific delivery, enhance cellular uptake, and reduce systemic toxicity. This strategy is particularly promising for delivering herbal antioxidants that modulate inflammation and oxidative stress in metabolic tissues[55].

Stimuli-Responsive Targeting: Stimuli-responsive or "smart" targeting systems are engineered to release their payload in response to specific biological cues at the disease site[56, 57]. These stimuli can be internal—such as acidic pH in inflamed tissues, elevated redox potential, or specific enzymes—or external, including temperature and magnetic fields. This approach ensures that drug release occurs only under precise conditions, enhancing treatment precision and minimizing side effects. For example, pH-responsive nanoparticles can release antioxidants preferentially in the acidic microenvironment of inflamed adipose tissue, enhancing local anti-inflammatory action[58]. These smart systems represent a significant advancement in personalized medicine and have broad implications for the efficient delivery of herbal therapeutics in complex metabolic disorders.

Table 1: Advantages of Nanodelivery over Conventional Systems

Conventional Herbal Form	Nanodelivery System
Low oral bioavailability	Enhanced absorption and cellular uptake
Rapid degradation	Protection from enzymatic metabolism
Poor targeting	Site-specific delivery
Need for high doses	Dose sparing with controlled release

Challenges and Future Perspectives

Safety and Toxicity: Despite the promising therapeutic potential of nanomedicine, concerns regarding the safety and toxicity of nanomaterials remain a major barrier to clinical translation. Certain nanoparticles can induce cytotoxic effects, provoke oxidative stress, and elicit undesired immune responses depending on their size, shape, surface chemistry, and composition. These interactions can lead to inflammation, genotoxicity, or organ-specific toxicity, especially in the liver, spleen, and kidneys. Moreover, the long-term effects of chronic exposure to nanomaterials are not fully understood, necessitating extensive preclinical and clinical toxicological studies. Biodegradability and clearance mechanisms of nanoparticles must be clearly defined to avoid bioaccumulation. Standardized protocols for toxicity testing are still lacking, complicating cross-study comparisons and regulatory approval. Therefore, comprehensive safety evaluations—including in vitro and in vivo assays—are crucial to mitigate risks and ensure biocompatibility before widespread clinical application. Addressing these concerns is essential to foster public trust and facilitate regulatory acceptance of nanotherapeutics.

Manufacturing and Scalability: The large-scale manufacturing and commercial scalability of nanomedicines pose considerable challenges, often limiting their transition from bench to bedside. Producing nanopharmaceuticals in a reproducible, cost-effective, and Good Manufacturing Practice (GMP)-compliant manner requires advanced infrastructure and stringent quality control. Variability in physicochemical properties such as particle size, charge, and encapsulation efficiency can significantly affect therapeutic outcomes, making batch-to-batch consistency critical. Moreover, many nanoparticle formulations involve complex synthesis processes, including multi-step purification, that may not be easily upscaled without compromising product integrity or functionality. The high cost of raw materials and specialized equipment also contributes to limited accessibility. For herbal-derived or natural product-based nanomedicines, ensuring consistency in plant extract composition adds another layer of complexity. To overcome these challenges, innovative approaches in process optimization, automation, and in-line monitoring are needed. Collaborations between academic researchers, industry, and regulatory bodies can help establish standardized protocols for scalable and economically viable nanomedicine production.

Regulatory Hurdles: Nanopharmaceuticals face significant regulatory hurdles due to the complexity of their structures and mechanisms of action. Regulatory frameworks have not fully caught up with the rapid advancements in nanotechnology, leading to inconsistencies in how different agencies assess safety, efficacy, and quality. For herbal-derived nanomedicines, these challenges are compounded by variability in the source materials and a lack of standardized characterization techniques. Unlike conventional drugs, nanomedicines may

require new testing paradigms to evaluate their pharmacokinetics, biodistribution, and toxicity profiles accurately. Furthermore, differences in classification—whether a product is considered a drug, biologic, or device—can influence the regulatory pathway and approval timelines. Comprehensive guidance documents are still evolving, which may lead to delays in development and commercialization. Harmonization of international regulations and development of nanotechnology-specific criteria for risk assessment, labeling, and post-market surveillance are essential to streamline approval processes and foster innovation in nanotherapeutic development, especially for complex formulations derived from natural sources.

Personalized Therapy: Personalized nanomedicine holds the promise of enhancing therapeutic efficacy and minimizing adverse effects by tailoring treatments to an individual's genetic and metabolic profile. Integration with omics technologies—such as genomics, proteomics, and metabolomics—enables the identification of biomarkers that predict disease susceptibility, drug response, and potential toxicity. These insights can guide the design of customized nanocarriers for targeted drug delivery, improving precision and clinical outcomes. However, implementing personalized therapy poses technical and logistical challenges. High-throughput data generation and analysis require sophisticated bioinformatics tools and interdisciplinary collaboration. Additionally, ethical concerns related to genetic data privacy and equitable access must be addressed. Standardization of data interpretation and integration with clinical workflows is also necessary to ensure scalability. Despite these hurdles, advances in nanotechnology and systems biology offer a synergistic platform for developing individualized therapeutic regimens, paving the way for a more proactive and patient-centric approach to treating complex diseases like metabolic disorders and cancers.

Integration with Digital Health: The convergence of nanomedicine with digital health technologies offers unprecedented opportunities for real-time disease monitoring, early diagnosis, and adaptive therapy, particularly in managing chronic metabolic disorders. Wearable sensors embedded with nanoscale components can detect physiological parameters such as glucose levels, heart rate, and metabolic markers with high sensitivity and accuracy. Coupled with artificial intelligence (AI) and machine learning algorithms, these devices can analyze vast amounts of data to provide predictive insights and personalized treatment recommendations. This integration allows for dynamic dosing, remote patient monitoring, and timely intervention, enhancing patient adherence and outcomes. However, challenges such as data security, device interoperability, regulatory approval, and user compliance need to be addressed. Furthermore, the development of multifunctional nanoplatforms capable of both therapeutic delivery and diagnostics (theranostics) remains in its early stages. Bridging nanomedicine with digital health requires multidisciplinary collaboration, robust infrastructure, and patient education to realize its full potential in precision medicine.

CONCLUSION

Targeted nanodelivery of herbal antioxidants represents a transformative approach to managing obesity and T2DM by enhancing the therapeutic performance of bioactive compounds and addressing underlying oxidative and inflammatory pathologies. Future research should focus on clinical validation, personalized nanomedicine strategies, and overcoming translational barriers to ensure these innovative therapies reach the populations most in need.

REFERENCES

1. Sulu, C., Yumuk, V.D.: Treat Obesity to Treat Type 2 Diabetes Mellitus. Diabetes Ther. 15, 611–622 (2024). https://doi.org/10.1007/s13300-024-01536-3
2. Aloo, S.O., Barathikannan, K., Oh, D.-H.: Polyphenol-rich fermented hempseed ethanol extracts improve obesity, oxidative stress, and neural health in high-glucose diet-induced *Caenorhabditis elegans*. Food Chem. X. 21, 101233 (2024). https://doi.org/10.1016/j.fochx.2024.101233
3. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obes. Med. 55, 100610 (2025). https://doi.org/10.1016/j.obmed.2025.100610
4. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
5. Chan, Y., Ng, S.W., Tan, J.Z.X., Gupta, G., Negi, P., Thangavelu, L., Balusamy, S.R., Perumalsamy, H., Yap, W.H., Singh, S.K., Caruso, V., Dua, K., Chellappan, D.K.: Natural products in the management of obesity: Fundamental mechanisms and pharmacotherapy. South Afr. J. Bot. 143, 176–197 (2021). https://doi.org/10.1016/j.sajb.2021.07.026
6. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. J. Cell. Mol. Med. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086
7. Udeozor, P.A., Ibiam, U.A., Uti, D.E., Umoru, G.U., Onwe, E.N., Mbonu, F.O., Omang, W.A., Ijoganu, S.I., Anaga, C.O., Mbah, J.O., Nwadum, S.K.: Antioxidant and Anti-Anemic Effects of Ethanol Leaf Extracts of Mucuna poggei and Telfairia occidentalis in Phenyl-Hydrazine-Induced Anemia in Wistar Albino Rats. Ibnosina J. Med. Biomed. Sci. 14, 116–126 (2022). https://doi.org/10.1055/s-0042-1756684

8. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Nna, V.U., Udeozor, P.A.: African walnuts attenuate ectopic fat accumulation and associated peroxidation and oxidative stress in monosodium glutamate-obese Wistar rats. Biomed. Pharmacother. Biomedecine Pharmacother. 124, 109879 (2020). https://doi.org/10.1016/j.biopha.2020.109879
9. Annett, S., Moore, G., Robson, T.: Obesity and Cancer Metastasis: Molecular and Translational Perspectives. Cancers. 12, 3798 (2020). https://doi.org/10.3390/cancers12123798
10. Cheng, Y., Liang, S., Zhang, S., Hui, X.: Thermogenic Fat as a New Obesity Management Tool: From Pharmaceutical Reagents to Cell Therapies. Biomedicines. 12, 1474 (2024). https://doi.org/10.3390/biomedicines12071474
11. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Nat. Prod. Commun. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
12. Kosmopoulou, D., Lafara, M.-P., Adamantidi, T., Ofrydopoulou, A., Grabrucker, A.M., Tsoupras, A.: Neuroprotective Benefits of Rosmarinus officinalis and Its Bioactives against Alzheimer's and Parkinson's Diseases. Appl. Sci. 14, 6417 (2024). https://doi.org/10.3390/app14156417
13. Alum, E.U.: Climate change and its impact on the bioactive compound profile of medicinal plants: implications for global health. Plant Signal. Behav. 19, 2419683 (2024). https://doi.org/10.1080/15592324.2024.2419683
14. Bhange, M., Telange, D.: Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: a comprehensive review. Discov. Oncol. 16, 77 (2025). https://doi.org/10.1007/s12672-025-01821-y
15. Ebrahimi, N., Manavi, M.S., Nazari, A., Momayezi, A., Faghihkhorasani, F., Rasool Riyadh Abdulwahid, A.-H., Rezaei-Tazangi, F., Kavei, M., Rezaei, R., Mobarak, H., Aref, A.R., Fang, W.: Nano-scale delivery systems for siRNA delivery in cancer therapy: New era of gene therapy empowered by nanotechnology. Environ. Res. 239, 117263 (2023). https://doi.org/10.1016/j.envres.2023.117263
16. Uti, D.E., Atangwho, I.J., Alum, E.U., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
17. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
18. Abbasi, H., Kouchak, M., Mirveis, Z., Hajipour, F., Khodarahmi, M., Rahbar, N., Handali, S.: What We Need to Know about Liposomes as Drug Nanocarriers: An Updated Review. Adv. Pharm. Bull. 13, 7–23 (2023). https://doi.org/10.34172/apb.2023.009
19. Buya, A.B., Mahlangu, P., Witika, B.A.: From lab to industrial development of lipid nanocarriers using quality by design approach. Int. J. Pharm. X. 8, 100266 (2024). https://doi.org/10.1016/j.ijpx.2024.100266
20. Gressler, S., Hipfinger, C., Part, F., Pavlicek, A., Zafiu, C., Giese, B.: A systematic review of nanocarriers used in medicine and beyond — definition and categorization framework. J. Nanobiotechnology. 23, 90 (2025). https://doi.org/10.1186/s12951-025-03113-7
21. Alami, M., Boumezough, K., Zerif, E., Zoubdane, N., Khalil, A., Bunt, T., Laurent, B., Witkowski, J.M., Ramassamy, C., Boulbaroud, S., Fulop, T., Berrougui, H.: In Vitro Assessment of the Neuroprotective Effects of Pomegranate (Punica granatum L.) Polyphenols Against Tau Phosphorylation, Neuroinflammation, and Oxidative Stress. Nutrients. 16, 3667 (2024). https://doi.org/10.3390/nu16213667
22. Alves, I., Araújo, E.M.Q., Dalgaard, L.T., Singh, S., Børsheim, E., Carvalho, E.: Protective Effects of Sulforaphane Preventing Inflammation and Oxidative Stress to Enhance Metabolic Health: A Narrative Review. Nutrients. 17, 428 (2025). https://doi.org/10.3390/nu17030428
23. Brito, D.V.C., Esteves, F., Rajado, A.T., Silva, N., Araújo, I., Bragança, J., Castelo-Branco, P., Nóbrega, C.: Assessing cognitive decline in the aging brain: lessons from rodent and human studies. Npj Aging. 9, 1–11 (2023). https://doi.org/10.1038/s41514-023-00120-6
24. Eyong, E.D., Iwara, I.A., Agwupuye, E.I., Agboola, A.R., Uti, D.E., Obio, W.A., Alum, E.U., Atangwho, I.J.: In vitro and in silico pharmaco-nutritional assessments of some lesser-known Nigerian nuts: Persea americana, Tetracarpidium conophorum, and Terminalia catappa. PLOS ONE. 20, e0319756 (2025). https://doi.org/10.1371/journal.pone.0319756
25. Okoh, O.S., Yakubu, A., Adegboyega, A.E., Uti, D.E., Obeten, U.N., Agada, S.A., Oluwaloni, F., Johnson, G.I., Mela, L.P., Asomadu, R.O.: Identification of some bioactive compounds from Trignonella foenumgraecum as possible inhibitors of PPARϒ for diabetes treatment through molecular docking studies, pharmacophore modelling and ADMET profiling: An in-silico study. Plos One. 18, e0284210 (2023)

26. Orji, O.U., Awoke, N.J., Uti, D.E., Obasi, O.D., Aja, P.M., Nwamaka, E.N., Umoru, G.U., Ogbu, P.N., Udoudoh, M.P., Alum, E.U., Ogbu, C.O., Oodo, S.I., Ibiam, U.A.: The Therapeutic Role of Gastrodin in Combating Insulin Resistance, Inflammation, and Oxidative Stress Induced by Bisphenol-A. Nat. Prod. Commun. 19, 1934578X241310096 (2024). https://doi.org/10.1177/1934578X241310096
27. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov. Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
28. Caturano, A., D'Angelo, M., Mormone, A., Russo, V., Mollica, M.P., Salvatore, T., Galiero, R., Rinaldi, L., Vetrano, E., Marfella, R., Monda, M., Giordano, A., Sasso, F.C.: Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications. Curr. Issues Mol. Biol. 45, 6651–6666 (2023). https://doi.org/10.3390/cimb45080420
29. Bertoncini-Silva, C., Vlad, A., Ricciarelli, R., Giacomo Fassini, P., Suen, V.M.M., Zingg, J.-M.: Enhancing the Bioavailability and Bioactivity of Curcumin for Disease Prevention and Treatment. Antioxidants. 13, 331 (2024). https://doi.org/10.3390/antiox13030331
30. Moetlediwa, M.T., Ramashia, R., Pheiffer, C., Titinchi, S.J.J., Mazibuko-Mbeje, S.E., Jack, B.U.: Therapeutic Effects of Curcumin Derivatives against Obesity and Associated Metabolic Complications: A Review of In Vitro and In Vivo Studies. Int. J. Mol. Sci. 24, 14366 (2023). https://doi.org/10.3390/ijms241814366
31. Li, Z., Zhang, Z., Ke, L., Sun, Y., Li, W., Feng, X., Zhu, W., Chen, S.: Resveratrol promotes white adipocytes browning and improves metabolic disorders in Sirt1-dependent manner in mice. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 34, 4527–4539 (2020). https://doi.org/10.1096/fj.201902222R
32. Mahjabeen, W., Khan, D.A., Mirza, S.A.: Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial. Complement. Ther. Med. 66, 102819 (2022). https://doi.org/10.1016/j.ctim.2022.102819
33. Salla, M., Karaki, N., El Kaderi, B., Ayoub, A.J., Younes, S., Abou Chahla, M.N., Baksh, S., El Khatib, S.: Enhancing the Bioavailability of Resveratrol: Combine It, Derivatize It, or Encapsulate It? Pharmaceutics. 16, 569 (2024). https://doi.org/10.3390/pharmaceutics16040569
34. Aghababaei, F., Hadidi, M.: Recent Advances in Potential Health Benefits of Quercetin. Pharmaceuticals. 16, 1020 (2023). https://doi.org/10.3390/ph16071020
35. Frenţ, O.-D., Stefan, L., Morgovan, C.M., Duteanu, N., Dejeu, I.L., Marian, E., Vicaş, L., Manole, F.: A Systematic Review: Quercetin—Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability. Int. J. Mol. Sci. 25, 12091 (2024). https://doi.org/10.3390/ijms252212091
36. Baldi, A., Abramovič, H., Poklar Ulrih, N., Daglia, M.: Tea Catechins. In: Xiao, J., Sarker, S.D., and Asakawa, Y. (eds.) Handbook of Dietary Phytochemicals. pp. 1–46. Springer, Singapore (2020)
37. Ai, X., Yu, P., Peng, L., Luo, L., Liu, J., Li, S., Lai, X., Luan, F., Meng, X.: Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases. Front. Pharmacol. 12, (2021). https://doi.org/10.3389/fphar.2021.762654
38. Li, A., Liu, Q., Li, Q., Liu, B., Yang, Y., Zhang, N.: Berberine Reduces Pyruvate-driven Hepatic Glucose Production by Limiting Mitochondrial Import of Pyruvate through Mitochondrial Pyruvate Carrier 1. EBioMedicine. 34, 243–255 (2018). https://doi.org/10.1016/j.ebiom.2018.07.039
39. Yin, J., Ye, J., Jia, W.: Effects and mechanisms of berberine in diabetes treatment. Acta Pharm. Sin. B. 2, 327–334 (2012). https://doi.org/10.1016/j.apsb.2012.06.003
40. Greco, G., Sarpietro, M.G.: Liposome-Assisted Drug Delivery in the Treatment of Multiple Sclerosis. Molecules. 29, 4689 (2024). https://doi.org/10.3390/molecules29194689
41. Pandolfi, L., Marengo, A., Japiassu, K.B., Frangipane, V., Tsapis, N., Bincoletto, V., Codullo, V., Bozzini, S., Morosini, M., Lettieri, S., Vertui, V., Piloni, D., Arpicco, S., Fattal, E., Meloni, F.: Liposomes Loaded with Everolimus and Coated with Hyaluronic Acid: A Promising Approach for Lung Fibrosis. Int. J. Mol. Sci. 22, 7743 (2021). https://doi.org/10.3390/ijms22147743
42. Yılmaz, E., Kacaroglu, D., Ozden, A.K., Aydogan, N.: Gold nanoparticles decorated FOLFIRINOX loaded liposomes for synergistic therapy of pancreatic cancer. Int. J. Pharm. 669, 125067 (2025). https://doi.org/10.1016/j.ijpharm.2024.125067
43. Chen, Y., Wu, Q., Zhang, Z., Yuan, L., Liu, X., Zhou, L.: Preparation of Curcumin-Loaded Liposomes and Evaluation of Their Skin Permeation and Pharmacodynamics. Molecules. 17, 5972–5987 (2012). https://doi.org/10.3390/molecules17055972
44. Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., Alcudia, A.: Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials. 10, 1403 (2020). https://doi.org/10.3390/nano10071403
45. kapoor, D. u, Garg, R., Gaur, M., Prajapati, B.G., Agrawal, G., Bhattacharya, S., Elossaily, G.M.: Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer. Results Chem. 6, 101167 (2023). https://doi.org/10.1016/j.rechem.2023.101167

46. Anwar, D.M., Hedeya, H.Y., Ghozlan, S.H., Ewas, B.M., Khattab, S.N.: Surface-modified lipid-based nanocarriers as a pivotal delivery approach for cancer therapy: application and recent advances in targeted cancer treatment. Beni-Suef Univ. J. Basic Appl. Sci. 13, 106 (2024). https://doi.org/10.1186/s43088-024-00566-x
47. Shehata, M.M.: Anticancer lipid-based drug delivery systems: Basic knowledge and recent applications. Nano TransMed. 3, 100054 (2024). https://doi.org/10.1016/j.ntm.2024.100054
48. Kalomiraki, M., Thermos, K., Chaniotakis, N.A.: Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int. J. Nanomedicine. 11, 1–12 (2015). https://doi.org/10.2147/IJN.S93069
49. Mittal, P., Saharan, A., Verma, R., Altalbawy, F.M.A., Alfaidi, M.A., Batiha, G.E.-S., Akter, W., Gautam, R.K., Uddin, Md.S., Rahman, Md.S.: Dendrimers: A New Race of Pharmaceutical Nanocarriers. BioMed Res. Int. 2021, 8844030 (2021). https://doi.org/10.1155/2021/8844030
50. Ashaolu, T.J.: Nanoemulsions for health, food, and cosmetics: a review. Environ. Chem. Lett. 19, 3381–3395 (2021). https://doi.org/10.1007/s10311-021-01216-9
51. Parseghian, L., Kahrarian, N., Arabanian, A.S., Moradi Alvand, Z., Massudi, R., Rahimi, M., Rafati, H.: Berberine-loaded nanoemulsions as a natural food preservative; the impact of femtosecond laser irradiation on the antibacterial activity. Heliyon. 10, e37283 (2024). https://doi.org/10.1016/j.heliyon.2024.e37283
52. Vagena, I.-A., Malapani, C., Gatou, M.-A., Lagopati, N., Pavlatou, E.A.: Enhancement of EPR Effect for Passive Tumor Targeting: Current Status and Future Perspectives. Appl. Sci. 15, 3189 (2025). https://doi.org/10.3390/app15063189
53. Subhan, M.A., Yalamarty, S.S.K., Filipczak, N., Parveen, F., Torchilin, V.P.: Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment. J. Pers. Med. 11, 571 (2021). https://doi.org/10.3390/jpm11060571
54. Zhang, Y., Wang, Y., Liu, J.: Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective. Genes Dis. 10, 825–847 (2023). https://doi.org/10.1016/j.gendis.2021.12.011
55. Cristelo, C., Nunes, R., Pinto, S., Marques, J.M., Gama, F.M., Sarmento, B.: Targeting β Cells with Cathelicidin Nanomedicines Improves Insulin Function and Pancreas Regeneration in Type 1 Diabetic Rats. ACS Pharmacol. Transl. Sci. 6, 1544–1560 (2023). https://doi.org/10.1021/acsptsci.3c00218
56. Ashrafizadeh, M., Mirzaei, S., Gholami, M.H., Hashemi, F., Zabolian, A., Raei, M., Hushmandi, K., Zarrabi, A., Voelcker, N.H., Aref, A.R., Hamblin, M.R., Varma, R.S., Samarghandian, S., Arostegi, I.J., Alzola, M., Kumar, A.P., Thakur, V.K., Nabavi, N., Makvandi, P., Tay, F.R., Orive, G.: Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression. Carbohydr. Polym. 272, 118491 (2021). https://doi.org/10.1016/j.carbpol.2021.118491
57. Parvin, N., Joo, S.W., Mandal, T.K.: Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases. J. Funct. Biomater. 16, 24 (2025). https://doi.org/10.3390/jfb16010024
58. Lee, H., Rho, W.-Y., Kim, Y.-H., Chang, H., Jun, B.-H.: CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations. Molecules. 30, 542 (2025). https://doi.org/10.3390/molecules30030542

CITE AS: Nyiramana Mukamurera P. (2025). Targeted Nanodelivery Systems of Herbal Antioxidants for Precision Management of Obesity and Type 2 Diabetes. INOSR Scientific Research 12(3):5-12. https://doi.org/10.59298/INOSRSR/2025/123512